Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up

被引：58

作者：

Balar, A. V. ^{[1
]}

Castellano, D. E. ^{[2
]}

Grivas, P. ^{[3
]}

Vaughn, D. J. ^{[4
]}

Powles, T. ^{[5
]}

Vuky, J. ^{[6
]}

Fradet, Y. ^{[7
]}

Lee, J. -L. ^{[8
]}

Fong, L. ^{[9
]}

Vogelzang, N. J. ^{[10
]}

Climent, M. A. ^{[11
]}

Necchi, A. ^{[12
,13
]}

Petrylak, D. P. ^{[14
]}

Plimack, E. R. ^{[15
]}

Xu, J. Z. ^{[16
]}

Imai, K. ^{[16
]}

Moreno, B. H. ^{[16
]}

Bellmunt, J. ^{[17
]}

de Wit, R. ^{[18
]}

O'Donnell, P. H. ^{[19
]}

机构：

[1] New York Univ Langone Hlth, Perlmutter Canc Ctr, New York, NY USA

[2] Hosp Univ 12 Octubre, Dept Med Oncol, Madrid, Spain

[3] Univ Washington, Fred Hutchinson Canc Ctr, Dept Med, Div Oncol, Seattle, WA USA

[4] Abramson Canc Ctr, Penn Med, Div Hematol Oncol, Philadelphia, PA USA

[5] Queen Mary Univ London, Dept Genitourinary Oncol, Barts Canc Inst, London, England

[6] Oregon Hlth & Sci Univ, Knight Canc Inst, Dept Med Oncol, Portland, OR USA

[7] Univ Laval, CHU Quebec, Dept Surg Urol, Quebec City, PQ, Canada

[8] Univ Ulsan, Coll Med, Dept Oncol, Asan Med Ctr, Seoul, South Korea

[9] Univ Calif San Francisco, Dept Med, San Francisco, CA USA

[10] Comprehens Canc Ctr Nevada, Dept Med Oncol, Las Vegas, NV USA

[11] Fdn Inst Valenciano Oncol, Dept Med Oncol, Valencia, Spain

[12] Univ Vita Salute San Raffaele, Dept Med Oncol, Milan, Italy

[13] IRCCS San Raffaele Hosp, Milan, Italy

[14] Yale New Haven Hlth, Dept Internal Med Med Oncol, Smilow Canc Hosp, New Haven, CT USA

[15] Fox Chase Canc Ctr, Dept Med Oncol, Philadelphia, PA USA

[16] Merck & Co Inc, Dept Med Oncol, Rahway, NJ USA

[17] Harvard Med Sch, Dana Farber Canc Inst, Dept Hematol & Oncol, Boston, MA USA

[18] Erasmus MC Canc Inst, Dept Med Oncol, Rotterdam, Netherlands

[19] Univ Chicago, Sect Hematol Oncol, Dept Med, Chicago, IL USA

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷 / 03期

关键词：

urothelial carcinoma; pembrolizumab; cisplatin-ineligible; cisplatin resistant; refractory; OPEN-LABEL; CHEMOTHERAPY; MULTICENTER; ATEZOLIZUMAB; IMVIGOR211; SURVIVAL;

D O I：

10.1016/j.annonc.2022.11.012

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Immune checkpoint inhibitors are a standard therapy in metastatic urothelial carcinoma (UC). Long-term follow-up is necessary to confirm durability of response and identify further safety concerns. Patients and methods: In KEYNOTE-045, patients with metastatic UC that progressed on platinum-containing chemotherapy were randomly assigned 1:1 to receive pembrolizumab or investigator's choice of paclitaxel, docetaxel, or vinflunine. Primary endpoints were progression-free survival per RECIST version 1.1 by blinded independent central review (BICR) and overall survival. In KEYNOTE-052, cisplatin-ineligible patients with metastatic UC received first-line pembrolizumab. The primary endpoint was objective response rate per RECIST version 1.1 by BICR. Results: A total of 542 patients (pembrolizumab, n = 270; chemotherapy, n = 272) were randomly assigned in KEYNOTE-045. The median follow-up was 62.9 months (range 58.6-70.9 months; data cut-off 1 October 2020). At 48 months, overall survival rates were 16.7% for pembrolizumab and 10.1% for chemotherapy; progression-free survival rates were 9.5% and 2.7%, respectively. The median duration of response (DOR) was 29.7 months (range 1.6+ to 60.5+ months) for pembrolizumab and 4.4 months (range 1.4+ to 63.1+ months) for chemotherapy; 36-month DOR rates were 44.4% and 28.3%, respectively. A total of 370 patients were enrolled in KEYNOTE-052. The median follow-up was 56.3 months (range 51.2-65.3 months; data cut-off 26 September 2020). The confirmed objective response rate was 28.9% (95% confidence interval 24.3-33.8), and the median DOR was 33.4 months (range 1.4+ to 60.7+ months); the 36-month DOR rate was 44.8%. Most treatment-related adverse events for pembrolizumab in either study were grade 1 or 2 and manageable, which is consistent with prior reports. Conclusion: With w5 years of follow-up, pembrolizumab monotherapy continued to demonstrate durable efficacy with no new safety signals in patients with platinum-resistant metastatic UC and as first-line therapy in cisplatin-ineligible patients.Clinical trial registry and ID: With ClinicalTrials.gov NCT02256436 (KEYNOTE-045); https://clinicaltrials.gov/ct2/show/ NCT02256436 and NCT02335424 (KEYNOTE-052); https://clinicaltrials.gov/ct2/show/NCT02335424

引用

页码：289 / 299

页数：11

共 26 条

[21] Roche Group Media Relations, ROCHE PROVIDES UPDAT
[22] BAYOU: A phase II, randomized, multicenter, double-blind, study of durvalumab (D) in combination with olaparib (O) for the first-line treatment of platinum-ineligible patients with unresectable, stage IV urothelial carcinoma (UC).
Rosenberg, Jonathan E.
Park, Se Hoon
Dao, Tu V.
Castellano, Daniel E.
Li, Jian-Ri
Mukherjee, Som
Howells, Kathryn
Dry, Hannah
Lanasa, Mark C.
Stewart, Ross
Bajorin, Dean F.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
[23] Primary results of STRONG: An open-label, multicenter, phase 3b study of fixed-dose durvalumab monotherapy in previously treated patients with urinary tract carcinoma
Sonpavde, Guru P.
Sternberg, Cora N.
Loriot, Yohann
Marabelle, Aurelien
Lee, Jae Lyun
Flechon, Aude
Roubaud, Guilhem
Pouessel, Damien
Zagonel, Vittorina
Calabro, Fabio
Banna, Giuseppe L.
Shin, Sang Joon
Vera-Badillo, Francisco E.
Powles, Thomas
Hellmis, Eva
Miranda, Paulo A. P.
Lima, Ana Rita
Emeribe, Ugochi
Oh, Sun Min
Hotte, Sebastien J.
[J]. EUROPEAN JOURNAL OF CANCER, 2022, 163 : 55 - 65
[24] Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract
Sternberg, Cora N.
Loriot, Yohann
James, Nicholas
Choy, Ernest
Castellano, Daniel
Lopez-Rios, Fernando
Banna, Giuseppe L.
De Giorgi, Ugo
Masini, Cristina
Bamias, Aristotelis
del Muro, Xavier Garcia
Duran, Ignacio
Powles, Thomas
Gamulin, Marija
Zengerling, Friedemann
Geczi, Lajos
Gedye, Craig
de Ducla, Sabine
Fear, Simon
Merseburger, Axel S.
[J]. EUROPEAN UROLOGY, 2019, 76 (01) : 73 - 81
[25] Atezolizumab Versus Chemotherapy in Patients with Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: A Long-term Overall Survival and Safety Update from the Phase 3 IMvigor211 Clinical Trial
van der Heijden, Michiel S.
Loriot, Yohann
Duran, Ignacio
Ravaud, Alain
Retz, Margitta
Vogelzang, Nicholas J.
Nelson, Betty
Wang, Jingjing
Shen, Xiaodong
Powles, Thomas
[J]. EUROPEAN UROLOGY, 2021, 80 (01) : 7 - 11
[26] Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer
Vuky, Jacqueline
Balar, Arjun V.
Castellano, Daniel
O'Donnell, Peter H.
Grivas, Petros
Bellmunt, Joaquim
Powles, Thomas
Bajorin, Dean
Hahn, Noah M.
Savage, Mary J.
Fang, Xiao
Godwin, James Luke
Frenkl, Tara L.
Moreno, Blanca Homet
de Wit, Ronald
Plimack, Elizabeth R.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (23) : 2658 - +

← 1 2 3 →